Servier

Welcome to our page. Servier is committed to therapeutic progress to serve patient needs. Neurology will constitute a future growth driver.

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide.

----

To report a suspected adverse event with a Servier drug 👉 https://bit.ly/435zpoI

06/01/2026

💬 “Even if I’m a small piece of this whole drug discovery process, I’m very motivated to know that artificial intelligence can help and can accelerate drug discovery for the patient.”

Meet Alban Arrault, R&D Chief A.I. Officer. He’s driving innovation by combining AI, data, and human collaboration to speed up the development of new medicines. 💊⚙️

🤝 With over 17 years at Servier, Alban shares how his journey from chemist to Chief A.I. Officer reflects a shared purpose: using technology and teamwork to deliver better treatments faster for patients worldwide.

Learn more about our digital transformation commitments and AI usage at https://bit.ly/44Pb6iE

04/01/2026

🔍 What if subtle behaviors could reveal the secrets of a rare neurological disease?

🧠 Spinocerebellar Ataxia Type 3 (SCA3) is a rare inherited disorder that gradually affects movement, balance, and coordination.

🐁 At Servier, postdoctoral researcher Marius Halliez is studying this disease using a system that tracks behavior continuously in a natural environment.

By observing subtle changes, researchers gain a clearer picture of disease progression, eventually helping to develop and test future treatments.

📖 Learn more below and in Sundari Journal No. 3 👉 https://bit.ly/4phpRSA

03/01/2026

🧪 Imagine creating dozens of potential medicines in one experiment.

🔎 At Servier, the Drug Design Small Molecules (DDSM) unit, where Raphael Steimbach works, uses High-Throughput Experimentation (HTE) to accelerate drug discovery.

🔬 By miniaturizing reactions and automating workflows, researchers can test hundreds of conditions and build diverse chemical libraries

Learn more about HTE and their research below and in Sundari Journal No. 3 👉 https://bit.ly/4phpRSA

02/01/2026

80+ young researchers, one shared ambition: innovate. Discover their latest insights in the 3rd edition of SUNDARI, created by the SHINEDocs community! 🚀

🧠 The SHINEDocs program brings together doctoral and postdoctoral students from our R&D teams and partner laboratories in France and around the world. These students represent the next generation of scientific innovation.

🎤 Through specialized training, career guidance, and networking activities, the program enables these young researchers to develop their skills and collaborate with one another. United by their passion for innovation, our SHINEDocs participants truly represent the next generation of medical research.

Discover their latest insights in Sundari Journal No. 3. 👉 https://bit.ly/4phpRSA

01/01/2026

🎉 Happy New Year 2026!
We wish you a wonderful, inspiring, and impactful year 2026! ✨

As we welcome 2026, our thoughts go first to the people who give meaning to everything we do: the patients, and all those who stand beside them — caregivers, partners, and our incredible teams around the world. 🌍

Thank you for inspiring us every single day. 🙏
This new year is an opportunity to reaffirm what defines us as a Group and what drives our commitment to therapeutic progress to serve patient needs.

Learn more about Servier 🔗 https://servier.com/en/

31/12/2025

🎉 In this special day, we wish you a Happy New Year!

As 2025 comes to an end, we want to thank all of you for being part of our journey.

Together, we achieved incredible milestones for patients worldwide, and this is just the beginning.

✨ May 2026 be a year filled with joy, health, and happiness in every way for you, our patients, families, colleagues, partners, and followers.

30/12/2025

Have you ever heard of Fragile X syndrome before❓

👧🧒 If not, that's understandable, as it affects only one in 7,000 males and one in 11,000 females worldwide. At Servier, we are committed to making a difference for these patients and their families.

🧬 That’s why in September 2025, we acquired a potential treatment for Fragile X syndrome, which is also the most common genetic cause of autism spectrum disorders.

This acquisition strengthens our neurology pipeline and supports our Servier 2030 ambition to address rare neurological diseases.

👉 Learn more at https://bit.ly/4iJEywi

29/12/2025

🤝 In September we joined forces with IDEAYA Biosciences to make a promising treatment for uveal melanoma available outside the U.S.

This rare eye cancer mainly affects older adults (60+ years old) with fair skin and light eyes, and treatment options are limited.

By partnering globally, we aim to bring hope to patients living with this rare and aggressive disease.

👉 Learn more at https://bit.ly/4pTNeT4

28/12/2025

🧠 Neurological disorders affect millions worldwide, and around 600 rare neurological conditions have been identified.

We prioritize diseases such as epilepsy, ataxia, amyotrophic lateral sclerosis (ALS), autoimmune myasthenia gravis, and others because they often lack effective therapeutic solutions.

Our ambition: develop innovative therapies to improve patients’ quality of life and address unmet medical needs.

👉 Learn more at https://bit.ly/3MLfMjd

27/12/2025

❤️ Cardiovascular diseases remain the leading cause of death worldwide, responsible for 17.7 million deaths every year, or 31% of all deaths.

At Servier, we focus on venous diseases, hypertension, and type 2 diabetes because these conditions impact millions of lives and require better prevention and treatment strategies.

🙌 Through research, partnerships, and education, we aim to help patients live longer and healthier lives.

👉 Learn more at https://bit.ly/48VsRz4

26/12/2025

🧬 In May 2025, we acquired a best-in-class precision therapy for acute leukemias from BioNova Pharmaceuticals. This innovative treatment will help us address critical needs in hematologic cancers and offer new solutions to patients.

📊 Did you know? Acute myeloid leukemia (AML) affects five out of 100,000 people living in Europe and over 20,000 new cases of AML were diagnosed in 2024 in the USA.

Through this acquisition, we reinforce our commitment to developing targeted therapies and improving outcomes for patients with rare and severe conditions.

👉 Learn more at https://bit.ly/4pS2jEH

Adresse

50, Rue Carnot
Suresnes
92150

Téléphone

+33 1 55 72 60 00

Site Web

https://servier.com/

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque Servier publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.

Raccourcis

Vous voulez que votre pratique soit Clinique la plus cotée à Suresnes ?

Type

Centre de recherche médicale

Our Story

Servier is an international pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France.

With a strong international presence in 149 countries and a turnover of € 4.2 billion in 2018, Servier employs 22.000 people worldwide.

Entirely independent, Servier reinvests 25% of its revenue (excluding generic drugs) in research and development and uses all its profits for development.